V617F is a gain of function mutation that promotes cytokine-independent growth of myeloid cells and accounts for a majority of myeloproliferative neoplasms (MPN). Mutations in p53 are rarely found in these diseases before acute leukemia transformation, but this does not rule out a role for p53 deregulation in disease progression. Using Ba/ F3-EPOR cells and ex vivo cultured CD34 þ cells from MPN patients, we demonstrate that expression of JAK2 V617F affected the p53 response to DNA damage. We show that E3 ubiquitin ligase MDM2 accumulated in these cells, due to an increased translation of MDM2 mRNA. Accumulation of the La autoantigen, which interacts with MDM2 mRNA and promotes its translation, was responsible for the increase in MDM2 protein level and the subsequent degradation of p53 after DNA damage. Downregulation of La protein or cell treatment with nutlin-3, a MDM2 antagonist, restored the p53 response to DNA damage and the cytokine-dependence of Ba/F3-EPOR-JAK2 V617F cells. Altogether, these data indicate that the JAK2 V617F mutation affects p53 response to DNA damage through the upregulation of La antigen and accumulation of MDM2. They also suggest that p53 functional inactivation accounts for the cytokine hypersensitivity of JAK2 V617F MPN and might have a role in disease progression.
JAK2
V617F is a gain of function mutation that promotes cytokine-independent growth of myeloid cells and accounts for a majority of myeloproliferative neoplasms (MPN). Mutations in p53 are rarely found in these diseases before acute leukemia transformation, but this does not rule out a role for p53 deregulation in disease progression. Using Ba/ F3-EPOR cells and ex vivo cultured CD34 þ cells from MPN patients, we demonstrate that expression of JAK2 V617F affected the p53 response to DNA damage. We show that E3 ubiquitin ligase MDM2 accumulated in these cells, due to an increased translation of MDM2 mRNA. Accumulation of the La autoantigen, which interacts with MDM2 mRNA and promotes its translation, was responsible for the increase in MDM2 protein level and the subsequent degradation of p53 after DNA damage. Downregulation of La protein or cell treatment with nutlin-3, a MDM2 antagonist, restored the p53 response to DNA damage and the cytokine-dependence of Ba/F3-EPOR-JAK2 V617F cells. Altogether, these data indicate that the JAK2 V617F mutation affects p53 response to DNA damage through the upregulation of La antigen and accumulation of MDM2. They also suggest that p53 functional inactivation accounts for the cytokine hypersensitivity of JAK2 V617F MPN and might have a role in disease progression.
Introduction
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic malignancies in which one or several myeloid lineages are abnormally amplified. This amplification results from the deregulation of hematopoietic stem cells (HSC) with a downstream selective proliferation advantage in late myeloid differentiation. MPNs frequently involve the deregulation of a tyrosine kinase due to the acquisition of theoretically a monogenetic abnormality in a HSC, the archetype of which is BCR/ ABL in chronic myelogenous leukemia. Most polycythemia vera (PV) and about half essential thrombocythemia and primary myelofibrosis (PMF) involve an acquired mutation in the Janus kinase 2 (JAK2) gene (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005) . Wild-type JAK2 encodes a tyrosine kinase that becomes activated downstream of several cytokine receptors after binding of their specific ligand, for example, erythropoietin (EPO) binding to its receptor (EPO-R). The most frequent JAK2 mutation is the V617F point mutation that lies in the autoinhibitory JH2 domain of the kinase, leading to JAK2 autophosphorylation and constitutive activation of downstream pathways (James et al., 2005; Kralovics et al., 2005; Levine et al., 2005) .
It has been postulated that essential thrombocythemia, PV and PMF might correspond to three steps of a unique disease, based on a JAK2 V617F gene dosage. Essential thrombocythemia patients display a monoallelic mutation of JAK2, most PV patients demonstrate a bi-allelic mutation, and progression from PV to MF may be due to the extension of homozygous JAK2 V617F mutations to all myeloid lineages and HSC. These three steps are recapitulated in all the mouse models generated with JAK2 V617F mutation (Lacout et al., 2006; Wernig et al., 2006; Tiedt et al., 2008; Shide et al., 2008) . Disease progression could be the consequence of additional genetic events, that is, cytogenetic abnormalities are observed in 20-40% of PMF compared with o10% of essential thrombocythemia and PV (Gangat et al., 2007; Kawamata et al., 2008; Tefferi et al., 2009 ) and accumulate when MPN progress to acute leukemia. JAK2 V617F mutation was suggested to induce an abnormal response to DNA damage through promoting homologous recombination in response to DNA double-strand breaks (Plo et al., 2008) , decreasing DNA damage-induced apoptosis through inhibiting Bcl-xL deamidation (Zhao et al., 2008) , and phosphorylating histone H3 tyrosine 41 residue (H3Y41), which excludes heterochromatin protein 1a (HP1a) and promotes expression of oncogenes such as LMO2 (Cummings et al., 2007; Dawson et al., 2009 ).
Inactivation of the p53 tumor suppressor protein, which has demonstrated pleiotropic functions in cell cycle, apoptosis and DNA repair (Smith and Seo, 2002; Bertrand et al., 2004) , could also favor homologous recombination (Akyuz et al., 2002; Bertrand et al., 2004) . p53-inactivating mutations were identified in o15% of chronic phase hematological malignancies, including chronic myelogenous leukemia (Kantarjian et al., 1987; Feinstein et al., 1991; Hernandez-Boussard et al., 1999) , PV (Gaidano et al., 1997) and PMF (Tsurumi et al., 2002; Reilly, 2005) and more than half of MPN in blast crisis (Gaidano et al., 1997; Tsurumi et al., 2002) . In the absence of mutation, p53 function can be inactivated by an increased expression of MDM2, an E3 ubiquitin ligase that binds to p53 and promotes its proteosomal degradation (Freedman et al., 1999) . MDM2 overexpression in transformed hematopoietic cells is associated with drug resistance and poor prognosis (Seliger et al., 1996; Faderl et al., 2000; Zhou et al., 2000) .
MDM2 accumulates in BCR/ABL-expressing cells (Trotta et al., 2003) and its downmodulation by an antisense oligonucleotide promotes growth factor deprivation-induced apoptosis (Goetz et al., 2001 ). The present study investigates JAK2 V617F impact on wildtype p53 functions. We demonstrate that, in JAK2 V617F expressing cells, DNA damage promote La-dependent increased translation of MDM2 mRNA, which decreases p53 expression. This functional inactivation of p53 is shown to account for the cytokine hypersensitivity of JAK2 V617F MPNs.
Results

JAK2
V617F inhibits the accumulation of p53 upon DNA damage After having confirmed the lack of mutation in the coding regions of the P53 gene in Ba/F3-EPOR cells (Liu et al., 2000; Goetz et al., 2001; Ishiguro et al., 2005) , we infected these cells with retroviruses encoding either JAK2 wt or JAK2 V617F (James et al., 2005) . The JAK2 protein levels were examined and showed that Ba/F3-EPOR-JAK2 wt and Ba/F3-EPOR-JAK2 V617F cells displayed 4.8 ± 0.4-and 5.5 ± 0.4-fold increase compared with control cells, respectively (Figure 1a) . STAT5 was constitutively phosphorylated in the absence of EPO in Ba/F3-EPOR-JAK2 V617F (Figure 1b ) (James et al., 2005) . Exposure of these cells to the genotoxic agent mitomycin C (MMC) (1 mg/ml) induced a time-dependent increase in both the expression of p53 and its phosphorylated form, [pS 15 ]-p53 that appears upon DNA damage. Compared with control Ba/F3-EPOR and Ba/F3-EPOR-JAK2 wt cells, p53 induction remained weak in Ba/F3-EPOR-JAK2
V617F
. Similarly, the kinetics of Bax induction, a transcriptional target of p53, was also reduced in Ba/F3-EPOR-JAK2 V617F compared with the Ba/F3-EPOR but differences with the Ba/F3-EPOR-JAK2 wt were weak ( Figure 1c) . These experiments were reproduced in independently derived cell lines (data not shown). Immunofluorescence analysis of [pS 15 ]-p53 demonstrated its nuclear localization in Ba/F3-EPOR and Ba/F3-EPOR-JAK2
wt that was strongly inhibited in Ba/F3-EPOR-JAK2 V617F cells (Sengupta et al., 2003) (Figure 1d ). Thus, JAK2
V617F expression appeared to reduce p53 stabilization and phosphorylation upon DNA damage. Using the protein synthesis inhibitor cycloheximide, we found that the half-life of p53 was around 60 min in Ba/F3-EPOR and Ba/F3-EPOR-JAK2 wt cells whereas it was decreased to o40 min in Ba/F3-EPOR-JAK2 V617F cells (Figure 1e ). MMC-induced p53 stabilization was restored by a 3-hour treatment of Ba/F3-EPOR-JAK2 V617F cells with 10 mM of the proteasome inhibitor lactacystin (Figure 1f) , indicating that JAK2 V617F may prevent p53 accumulation in response to DNA damage by enhancing its degradation.
These experiments were repeated with erythroblasts derived from CD34 þ cells isolated from peripheral blood of G-CSF-mobilized healthy donors or JAK2 V617F -positive PV and MF patients. CD34
þ cells were cultured in serum-free medium supplemented with interleukin (IL)-3, EPO and SCF for 7 days, and then treated with MMC. Again, we observed that the expression of p53 and [pS 15 ]-p53 were significantly reduced in patients (n ¼ 15) compared with control (n ¼ 7) cells (Figures 2a and b) . This reduced expression was associated with a significant decrease in BAX and PUMA mRNA expression in MF compared with control cells (Figures 2c and d) . In PV samples, the decrease did not reach significance (Figures 2c and d ). This could be related to a more inconstant JAK2 V617F burden in CD34 þ -derived erythroblasts from PV (from 17% to 85%) compared with MF patients (always higher than 50%).
Altogether these results show that JAK2 V617F inhibits p53 expression and function after genotoxic stress by enhancing its degradation.
JAK2
V617F stimulates MDM2 expression p53 degradation is mainly regulated by the ubiquitin ligase activity of MDM2. Therefore, one could hypothesize that JAK2 V617F -induced p53 degradation was mediated by increased MDM2 levels. MDM2 was barely detectable in Ba/F3-EPOR and Ba/F3-EPOR-JAK2 wt cells whereas both protein isoforms, namely p90 and p76, were readily detected in Ba/F3-EPOR-JAK2 V617F cells ( Figure 3a ) (Mendrysa et al., 2001 ). In these latter cells, MDM2 expression level decreased either upon exposure to CMP6, a JAK inhibitor, in a dose-dependent manner or upon treatment with AZD1480, a JAK2 inhibitor (Figures 3b and c) . Figure 1A) . In addition, the protein half-life measured upon treatment with cycloheximide V617F cells were untreated or treated with the proteasome inhibitor lactacystin (10 mM) for 3 h. Then, cells were exposed to 1 mg/ml MMC for 3 or 6 h. Extracts were probed by western blotting for p53 protein levels. One representative out of three independent experiments is shown.
V617F negatively regulates p53 via La antigen M Nakatake et al ]p53 inhibition after 6 h of MMC treatment in erythroblasts from patients (n ¼ 15) compared with controls (n ¼ 7). * (Po0.05). (c, d) Erythroblasts from G-CSF-mobilized donors (n ¼ 6) or JAK2 V617F positive-patients with PV (n ¼ 8) or MF (n ¼ 7) were treated with MMC (1 mg/ml) for 6 h. BAX (c) or PUMA (d) mRNA levels were quantified by real-time PCR using primers detailed in Table S2 . Results were normalized using b2M mRNA and fold changes after MMC treatment were calculated. *(Po0.05). NS: nonsignificant. þ cells from a control donor were also tested. Cells were cultured for 5 days in medium containing SCF, IL-3, IL-6, FLT3-L and EPO before analyzing MDM2 expression by immunoblot.
V617F negatively regulates p53 via La antigen M Nakatake et al synthesized MDM2 in Ba/F3-EPOR-JAK2 V617F compared with control cells (Supplementary Figure 1D) . Together, these results suggested that JAK2 V617F stimulates MDM2 protein levels via enhanced translation.
V617F increases La protein expression and interaction with MDM2 mRNA To test whether the RNA binding protein La, known to stimulate MDM2 mRNA translation (Trotta et al., 2003) , was at the basis of the increased MDM2 protein level, we first measured the La protein levels in the three Ba/F3-EPOR cell lines and in CD34 þ cells from patients. Levels of La protein were examined and fold changes were 1.5 ± 0.6 in Ba/F3-EPOR-JAK2 wt cells and 2.4 ± 0.7 in Ba/F3-EPOR-JAK2
V617F cells compared with control cells (Figure 4a ). Similarly, a significant increase in La protein correlated with MDM2 protein was observed in JAK2 V617F -positive patients with PV and MF (Figures 3c and 4b/c). Interestingly, patients with barely detectable La (#8 and #11) displayed low levels of MDM2. To confirm the role of La in MDM2 mRNA translation, we performed quantitative reverse-transcriptase (qRT) PCR on RNA from the three cell lines that was co-immunoprecipitated by an anti-La antibody. mY1 scRNA and U5 snRNA were used as positive and negative controls of La interactions,
respectively. An interaction between MDM2 mRNA and the La protein was augmented in Ba/F3-EPOR-JAK2 V617F cells compared with Ba/F3-EPOR or Ba/F3-EPOR-JAK2 wt cells (Figure 4d ).
La knock down restores p53 induction in response to DNA damage To further test the role of the La protein on p53 expression in Ba/F3-EPOR-JAK2 V617F cells, we used two retroviruses encoding distinct short hairpin (sh)RNAs directed against the murine La. Both shRNAs resulted in a twofold reduction in the La protein level (Figure 5a ). We observed that the increase in p53 expression was restored in response to MMC for 6 h with the two shLa compared with control shscr in Ba/ F3-EPOR-JAK2 V617F (Figure 5b ). Of note, the p53 level in cells transduced with shLa-2 was close to that seen in MMC-treated Ba/F3-EPOR cells, while shLa-3 resulted in a lower p53 expression restoration. Interestingly, shLa-2 abolished MDM2 protein expression whereas shLa-3 did not (Figure 5a ). This might be explained by a positive p53 transcriptional regulation of MDM2 in equilibrium with the induced translational defect. We next investigated La knock down in human cells. Toward this end, we used a lentiviral vector encoding either a shRNA targeting the human La or a control Immunoprecipitates were assayed by subjecting to qRT-PCR to detect MDM2 mRNA, U5 snRNA and mY1 scRNA transcripts. Histograms represent the fold enrichment compared with immunoglobulin G control immunoprecipitates. *Po0.05, **Po0.01.
V617F negatively regulates p53 via La antigen M Nakatake et al scramble sequence to infect erythroblasts obtained from PV or MF patients. Immunoblots revealed that the La level was reduced by about 30-80% in shLa-treated cells (Figures 5c and f) . In erythroblasts from patients treated with MMC, p53 and phosphorylated [pS 15 ]p53 accumulated more efficiently in shLa-treated cells than in shscrtreated cells (Figures 5d, e and g ). These results show that the La antigen is responsible for the control of p53 regulation after a genotoxic treatment in JAK2 V617F -expressing cells.
Cytokine independence generated by JAK2 V617F involves p53 degradation In order to explore the biological consequences of p53 upregulation by JAK2 V617F , we evaluated either the effect of shRNAs directed against the murine La or the effect of the MDM2 antagonist, Nutlin-3 on cell growth. We have previously shown that, in contrast to Ba/ F3-EPOR cells, Ba/F3-EPOR-JAK2 V617F could grow independently of any cytokine (James et al., 2005) . To check whether p53 upregulation could be involved in V617F cells were infected with shRNAs. p53 stabilization was evaluated after 6 h exposure to 1 mg/ml MMC by western blotting. Fold changes were calculated by densitometry compared with EPOR after 6-h MMC treatment. (c, d, e, f, g) CD34 þ cells from JAK2 V617F -positive PV and MF blood samples were infected with shRNA (scr or shLa). Three days after infection, cells were sorted on GFP expression and cultured for 4 days before La expression level was assessed by western blotting in erythroblasts (c, f). Erythroblasts were exposed to 1 mg/ml MMC for indicated times and p53 or [pS 15 ]p53 were detected by immunoblotting (d, e, g). d and e experiments were from the same patient repeated independently. Fold changes were calculated by densitometry compared with scr after MMC treatment (d, e, g). Data on e were juxtaposed from the same gel.
V617F negatively regulates p53 via La antigen M Nakatake et al cytokine independence, we transduced shLa-2 or shLa-3 into Ba/F3-EPOR-JAK2 V617F cells to downregulate the expression level of La antigen. Both the shLa resulted in a significant reduction in the cell proliferation rate in the absence of cytokine (Figure 6b) , which was corrected when cells were grown in the presence of EPO (Figure 6a ). When cells were grown in the presence of Nutlin-3 (10 mM), an inhibitor of the p53/MDM2 interaction, p53 expression levels were highly increased (Figures 6c and d, inserts) . No major impact was observed on Ba/F3-EPOR cell growth in the presence of EPO (Figure 6c ). However, a major inhibitory effect on Ba/F3-EPOR-JAK2 V617F cell growth in the absence of cytokine was demonstrated while this growth inhibitory effect was corrected by the addition of EPO (Figure 6d) .
Altogether, these results suggest that p53 degradation by MDM2 has a central role in the cytokine independence induced by JAK2
V617F
.
Discussion
The present study demonstrates that JAK2 V617F somatic mutation alters p53 response to DNA damage through upregulation of La antigen that increases MDM2 protein translation. Our results argue also for a role of p53 inhibition in the cytokine independence of JAK2 V617F -mutated cells. Even though p53 mutations are rare in MPN (Gaidano et al., 1997; Tsurumi et al., 2002; Reilly, 2005) , the abnormal regulation of the protein in response to some stresses may account for disease progression.
The murine Ba/F3-EPOR cell line expresses a wildtype p53 and fails to express p19 ARF (Liu et al., 2000; Goetz et al., 2001; Ishiguro et al., 2005) . p53 protein is not detectable in these cells in the absence of stress and accumulates in response to a genotoxic agent, which correlates with its phosphorylation on serine 15 residue and its nuclear redistribution. Overexpression of wildtype JAK2 did not affect this ARF-independent, p53 response to DNA damage. In contrast, this response was abolished by expression of the V617F mutant of JAK2. The defective p53 response to DNA damage was specifically observed in CD34 þ -derived erythroid progenitors from patients with JAK2 V617F MPN, as confirmed by studying induction of two p53 target genes, BAX and PUMA. The higher JAK2 V617F burden in CD34
þ -derived erythroid progenitors from MF 
JAK2
V617F negatively regulates p53 via La antigen M Nakatake et al compared with PV patients may account for the stronger inhibition of p53 response in MF samples.
Both enhanced protein translation (Takagi et al., 2005) and decreased degradation (Freedman et al., 1999) can account for p53 accumulation in response to genotoxic stress. Our results argue for an increased degradation of p53 in the presence of JAK2
V617F
. The half-life of the protein is decreased in the absence of any stress and the proteasome inhibitor lactacystin restores p53 induction in response to a genotoxic stress. The RING domain-containing protein MDM2 ubiquitinates p53 C-terminus, promotes its degradation by the 26S proteasome and can also affect P53 mRNA translation (Candeias et al., 2008) . MDM2 was found overexpressed both in Ba/F3 cell lines and primary cells expressing JAK2
. MDM2 mRNA levels and MDM2 protein half-life were unchanged in JAK2 wt compared with JAK2 V617F -overexpressing cells in which the increase in MDM2 protein level was related to an enhanced translation.
An increased translation of MDM2 was described in Burkitt's lymphoma cells and in chronic myelogenous leukemia through interaction of an intercistronic region located in exon 2 of MDM2 mRNA with the La autoantigen (Capoulade et al., 1998; Trotta et al., 2003) . This conserved RNA-binding phosphoprotein interacts with a large variety of ligands and displays several functions, including inhibition of exonucleolytic digestion of RNA polymerase III transcripts, regulation of the processing of 5 0 and 3 0 ends of pre-tRNA precursors, and RNA chaperoning. The protein is also involved in the control of translation of specific mRNAs such as XIAP and MDM2 mRNAs (Holcik and Korneluk, 2000; Trotta et al., 2003) . We show that La protein accumulates in JAK2 V617F cells and co-precipitates with MDM2 mRNA to promote MDM2 synthesis. La depletion by shRNAs favors p53 phosphorylation and stabilization while increasing the expression of the p53 target BAX after MMC treatment. Although the two tested shRNA demonstrated similar effect on p53 expression, shLa-2 strongly inhibited MDM2 expression whereas shLa-3 did not, which could be related to a negative feedback loop between p53 and MDM2 in which MDM2-decreased translation is compensated by an increased transcription (Freedman et al., 1999) . Altogether, JAK2
V617F is shown for the first time to induce a ribonucleoprotein and further studies should indicate whether others ribonucleoproteins are regulated similarly (Perrotti and Neviani, 2007) . La upregulation was prevented by potent chemical inhibitors of JAK2 (Supplementary figure 2) , and may be partially dependent on two mechanisms: (i) one is at the mRNA level as the use of JAK2 inhibitor (AZD1480) decreases LA mRNA; (ii) another is via the PI3K/AKT/mTOR pathway in a transcription-independent way, suggesting that La mRNA translation could be regulated partially through major mTOR targets including S6K and 4EBP-1 (Jastrzebski et al., 2007) .
EPO-independent proliferation of JAK2
-expressing cells is the hallmark of MPNs. Disruption of MDM2/p53 interaction by Nutlin-3 or depletion of La protein strongly reduced the EPO-independent growth of Ba/F3-EPOR-JAK2 V617F cells whereas proliferation in the presence of EPO was barely affected. The role of the La/MDM2/p53 pathway to the MPN pathogenesis raised the possibility to use Nutlin-3 alone or in combination for treatment of the JAK2 V617F -positive MPN patients. Such a treatment could reduce the malignant clone in the chronic phase of the disease before any mutation in P53. Nutlin-3 and another MDM2 inhibitor, MI-63, which have been tested in pre-clinical studies or early phase clinical trials (Vassilev et al., 2004; Shangary and Wang, 2009 ) could be an alternative or complement to currently developed JAK2 inhibitors.
A role of MDM2/p53 in the regulation of erythropoiesis has been suggested by the defects in early and late erythropoiesis observed in mice with a conditional knockout of MDM2 (Maetens et al., 2007) . Noteworthy, the pathogenesis of the anemia in 5q-and Diamond-Blackfan syndromes could be related to p53 induction by a ribosomal stress (Sieff et al., 2010) , whereas p53 is downregulated by oncogenes such as Fli-1 or PU1/Spi-1 in erythroleukemia (Wong et al., 1999; Scolan et al., 2001) . Consequently, mis-regulation of p53 in erythropoiesis could lead either to anemia or to proliferative disorders.
Altogether, these data show that JAK2 V617F negatively regulates p53 stabilization by enhancing MDM2 translation via La expression. They suggest that p53 functional inactivation is a key event, both in the cytokine hypersensitivity of JAK2 V617F MPNs and in the disease progression to acute leukemia by allowing the accumulation of secondary genetic events.
Materials and methods
Materials
Fetal bovine serum was from Stem Cell Technologies (Meylan, France). Iscove's modified Dulbecco's medium and Dulbecco's modified Eagle medium were from Invitrogen (Cergy Pontoise, France). Human recombinant EPO, SCF, FLT3-L and IL-3 were generous gifts from Amgen (Neuilly, France) and TPO from Kirin (Tokyo, Japan). Recombinant human IL-6 was provided by S Burstein (Oklahoma City, OK, USA). Proteasome inhibitor lactacystin, protein synthesis inhibitor cycloheximide, MDM2 antagonist Nutlin-3 and various inhibitors (LY294002, AKT inhibitor, CMP6, PD98059, rapamycin, RAD001) were purchased from Calbiochem (MERCK Chemicals Ltd., Beeston Nottingham, UK). JAK2 inhibitor AZD1480 was kindly provided by AstraZeneca Pharmaceuticals (Waltham, MA, USA). Mitomycin C was purchased from SIGMA (Saint Quentin Fallavier, France).
Cell lines
The murine pro B Ba/F3-EPOR cell line and derivative cell lines were cultured in Dulbecco's modified Eagle medium complemented with 10% fetal bovine serum and in the presence of 1 U/ml EPO. JAK2 V617F negatively regulates p53 via La antigen M Nakatake et al Plasmids, DNA manipulations, production of retrovirus or lentivirus In order to downmodulate La expression, lenti-or retrovirusmediated shRNAs were used, as previously described (Berthebaud et al., 2005) . Retroviral vectors encoding murine shRNALa were purchased from Origene Technologies (pRS shRNA vector) (Rockville, MD, USA). Retrovirus particles were produced as previously described (Plo et al., 2008) . Oligonucleotides coding for human shRNA-La (5 0 -GATCCCCC CAAGGCAGAACTCATGGAAATTCAAGAGATTTCCA TGAGTTCTGCCTTGGTTTTTGGAAA-3 0 ) were synthesized (Eurogenotec, Seraing, Belgium), hybridized and inserted into a pBlue Script containing the human H1 promoter. H1-shRNA-La or H1-shRNA-SCR (scramble sequence used as a control) cassettes were inserted into a pRRL vector (pRRLsin-PGK-eGFP-WPRE, Genethon, Evry, France). Lentivirus particles were produced as previously described (Plo et al., 2008) . Ba/F3-EPOR cells were infected with retrovirus containing the murine shRNA-La and were selected with puromycin (1 mg/ml). CD34 þ cells from patients were infected with lentivirus containing human shRNA-La and GFP and GFP-positive cells were selected 24 h later on a FACSDiva cell sorter (BD Biosciences, le Pont de Claix, France).
Patients
Peripheral blood samples were collected from PV and MF patients. MPN was diagnosed according to the modified polycythemia vera Study Group criteria for PV (Michiels et al., 2000) and the Italian criteria for MF (Barosi et al., 1999) . Only JAK2
V617
-positive patients were selected after analyses of their mutational status using fluorescent competitive probes for quantitative real-time PCR as reported previously (James et al., 2005; Levine et al., 2005) . Control peripheral blood samples were collected from patients undergoing leukapheresis. The study was approved by the Local Research Ethics Committee from the Hoˆtel-Dieu (Paris, France) and Henri Mondor (Cre´teil, France) hospitals. Informed consent was obtained from each patient in accordance with the Declaration of Helsinki.
Purification of CD34
þ cells and cultures Mononuclear cells were separated over a Ficoll density gradient and CD34 þ cells were purified by a double-positive magnetic cell sorting system (AutoMACS, Miltenyi Biotec, Paris, France). CD34 þ cells were amplified for 5 days in Iscove's modified Dulbecco's medium with penicillin/streptomycin/glutamine, alpha-thioglycerol, bovine serum albumin, a mixture of sonicated lipids and insulin-transferrin, in the presence of five recombinant human cytokines (25 ng/ml SCF, 100 U/ml IL-3, 10 ng/ml TPO, 10 ng/ml IL-6, 1 ng/ml FLT3-L). Alternatively, CD34 þ cells were cultured 7 days in Iscove's modified Dulbecco's medium with penicillin/streptomycin/glutamine, alpha-thioglycerol, bovine serum albumin, a mixture of sonicated lipids and iron saturated transferrin, in the presence of three recombinant human cytokines (25 ng/ml SCF, 100 U/ml IL-3, 1 U/ml EPO), which resulted in more than 80% erythroblasts.
Western blot analysis, immunoprecipitation and metabolic labeling Western blot analysis were done as previously described (Plo et al., 2008) Immunoprecipitates were washed with HNTG buffer containing 50 mM HEPES (pH 7.0), 10% glycerol, 0.3% Triton X-100, 150 mM NaCl, 1 mM NaVO 4 . Immunoprecipitated proteins were resolved by SDS-polyacrylamide gel electrophoresis 7% under denaturing conditions, transferred onto nitrocellulose and newly synthesized [ 35 S]methionine-MDM2 was visualized after exposure to X-AR films. Alternatively, total MDM2 proteins were detected using the ECL detection kit. Quantifications were calculated by densitometry using with ImageJ Software (National Institutes of Health, Bethesda, MD, USA).
Immunofluorescence analysis
Immunofluorescence were done as previously described (Plo et al., 2008 ) using a rabbit anti- [pS 15 ]p53 antibody (1/100) (Cell Signaling Technology) and Alexa 488-conjugated anti-rabbit immunoglobulin G appropriately.
Real-time quantitative RT-PCR Primers and internal probes for qRT-PCR were designed using Primer Express Software (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) and are listed in Supplementary  Tables S1 and S2 . Total RNAs from cells were isolated using Trizol and complementary DNAs were synthesized by SuperScript II Reverse Transcriptase (Invitrogen). PCRs were carried out in the ABI Prism GeneAmp 7500 Sequence Detection System (Perkin-Elmer Applied Biosystems) using the Power SYBR Green PCR Master Mix (ABI) containing the specific primers (1.2 mM). The expression levels of all genes were expressed relatively to b2 microglobulin or GAPDH.
qRT-PCR of coimmunoprecipitated RNA Whole cell extracts were prepared from Ba/F3-EPOR cells and derivatives (5 Â 10 6 ) using NET-2 buffer (50mM Tris-HCl (pH ¼ 7.5). 150 mM NaCl, 0.5% NP-40). Whole cell extracts were precleared using protein G sepharose (PGS). Precleared lysates were immunoprecipitated with either 3 mg anti-La (BD Transduction Laboratories) or control anti-immunoglobulin G antibodies overnight at 4 1C. Then, protein G sepharose was added for 2 h at 4 1C. The beads were washed six times with cold NET-2 and extracted twice with 100 ml 50 mM Tris-Cl (pH 7.5), 2% SDS. Each incubation was for 20 min at 37 1C. Total RNA was purified from equivalent amounts of supernatants and input, as well as from all immunoprecipitated materials using phenol, chloroform, isoamylalcohol followed by ethanol precipitation, sodium acetate (3 M) and glycogen 30 min at À80 1C. RT-PCR was performed using the Superscript II Reverse Transcriptase. qPCRs were carried out as indicated above with the specific primers (1.2 mM). Primers (5 0 to 3 0 ): MDM2: TTCTCCTGCGGCCTCCAGGC and AGCAATGGTTTTGGTCTAACCAGA; mY1: GGCTGG TCCGAAGGTAGTG and AAAGACTAGTCAAGTGCAG TAGTGAGA; U5: GATACTCTGGTTTCTCTTCAGATCG and CCTCAAAAAATTGGTTTAAGACTCAG.
Statistical analysis
Results are means ± SD of at least three independent experiments. Statistical analysis of the cell lines was performed using the Student's t-test. Statistical significance (Po0.05) is indicated by *.
